U-Factor Holdings Decides to Adopt Toyota's 'WAVEBASE' for Drug Discovery Using Stem Cell Supernatant 'U-Factor® Fluid'
U-Factor Holdings has decided to adopt Toyota Motor's data analysis system 'WAVEBASE' to enhance drug discovery research involving its stem cell supernatant 'U-Factor® fluid.' Implementation is scheduled for April 2026.
📋 Article Processing Timeline
- 📰 Published: March 31, 2026 at 19:00
- 🔍 Collected: April 1, 2026 at 13:39 (18h 39m after Published)
- 🤖 AI Analyzed: April 22, 2026 at 06:25 (496h 46m after Collected)
U-Factor Holdings Inc. (Headquarters: Chiyoda-ku, Tokyo; CEO: Hidehiro Ijima; hereinafter referred to as 'our company') has decided to adopt the data analysis system 'WAVEBASE' provided by Toyota Motor Corporation (Headquarters: Toyota City, Aichi Prefecture; President: Koji Sato; hereinafter referred to as 'Toyota'). Our company will revamp the analysis framework in our drug discovery research by utilizing various cross-sectional data, including protein data from stem cell supernatant fluids.
We have initiated preparations for implementation, including requirements definition and environmental design, targeting a launch in April 2026.
1. Key Points of This Release
- Decided to adopt 'WAVEBASE' to strengthen the analysis infrastructure in drug discovery research for stem cell supernatant fluid.
- Established an integrated analysis framework targeting protein data of stem cell supernatant fluid and other relevant data.
- Implementation is scheduled to begin around April 2026.
2. Background
Drug discovery research involving stem cell supernatant fluid requires handling diverse data across multiple domains. Our company has been considering strengthening our analysis infrastructure, recognizing the handling of research data and the streamlining of analysis processes as crucial challenges.
3. This Initiative (Roles of Each Company)
Our company: Designing data integration and analysis operations in drug discovery research, and utilizing them in R&D.
Toyota: Providing the data analysis system 'WAVEBASE' and offering technical support.
4. Future Schedule
Scheduled Implementation: April 2026
*The timing of the contract signing and implementation may change depending on future discussions and procedures.
5. About 'WAVEBASE'
'WAVEBASE' is a cloud-based data analysis service provided by Toyota.
We decided to adopt it to support analysis tasks targeting the diverse data in our research and development.
6. What is our proprietary stem cell supernatant fluid 'U-Factor® fluid'?
Our company purifies the supernatant liquid obtained during the stem cell cultivation process using our proprietary technology, and we named this high-purity stem cell supernatant fluid 'U-Factor® fluid' (Registration Number: No. 6396893). It contains a massive amount of cytokines (proteins with physiological activity) secreted by stem cells. We believe that the U-Factor® fluid, refined through continuous improvements and a special purification method, holds tremendous potential regarding safety and efficacy.
7. Company Profile
U-Factor Holdings Inc.
Location: 6-4-6 Kojimachi, Chiyoda-ku, Tokyo 102-0083
Representative: Hidehiro Ijima, CEO
We have initiated preparations for implementation, including requirements definition and environmental design, targeting a launch in April 2026.
1. Key Points of This Release
- Decided to adopt 'WAVEBASE' to strengthen the analysis infrastructure in drug discovery research for stem cell supernatant fluid.
- Established an integrated analysis framework targeting protein data of stem cell supernatant fluid and other relevant data.
- Implementation is scheduled to begin around April 2026.
2. Background
Drug discovery research involving stem cell supernatant fluid requires handling diverse data across multiple domains. Our company has been considering strengthening our analysis infrastructure, recognizing the handling of research data and the streamlining of analysis processes as crucial challenges.
3. This Initiative (Roles of Each Company)
Our company: Designing data integration and analysis operations in drug discovery research, and utilizing them in R&D.
Toyota: Providing the data analysis system 'WAVEBASE' and offering technical support.
4. Future Schedule
Scheduled Implementation: April 2026
*The timing of the contract signing and implementation may change depending on future discussions and procedures.
5. About 'WAVEBASE'
'WAVEBASE' is a cloud-based data analysis service provided by Toyota.
We decided to adopt it to support analysis tasks targeting the diverse data in our research and development.
6. What is our proprietary stem cell supernatant fluid 'U-Factor® fluid'?
Our company purifies the supernatant liquid obtained during the stem cell cultivation process using our proprietary technology, and we named this high-purity stem cell supernatant fluid 'U-Factor® fluid' (Registration Number: No. 6396893). It contains a massive amount of cytokines (proteins with physiological activity) secreted by stem cells. We believe that the U-Factor® fluid, refined through continuous improvements and a special purification method, holds tremendous potential regarding safety and efficacy.
7. Company Profile
U-Factor Holdings Inc.
Location: 6-4-6 Kojimachi, Chiyoda-ku, Tokyo 102-0083
Representative: Hidehiro Ijima, CEO